SEC 01design + devREV 2023
Calidi Biotherapeutics
SEC 02
Overview
Website for a clinical-stage biotech company developing targeted immunotherapies for cancer. Needed to balance scientific credibility with accessibility for investors.
SEC 03
The Work
Designed and built the full site. Clean, authoritative visual language with generous whitespace and clear information hierarchy. Pipeline pages, investor content, team bios — all responsive and fast.
SEC 04
Engagement
After the 2023 redesign, Calidi kept DXD on a web-mastering and maintenance retainer for ongoing updates.
SEC 06
Tech
[ Webflow ][ Custom Design ][ UI/UX ][ CMS ]
SEC 07